Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8969972 | 1.00 | CHRM2 (0.34) | CHRM2CHRM4CHRM3SLC6A4KMT2A | |
| SCHEMBL68475 | 0.86 | CHRM2 (0.38) | CHRM2CHRM4CHRM3KMT2ACYP3A4 | |
| SCHEMBL14593867 | 0.82 | CHRM2 (0.35) | CHRM2CHRM4CHRM3SLC6A4KMT2A | |
| SCHEMBL2642097 | 0.82 | CHRM2 (0.35) | CHRM2CHRM4CHRM3SLC6A4KMT2A | |
| SCHEMBL14593887 | 0.82 | CHRM2 (0.35) | CHRM2CHRM4CHRM3SLC6A4KMT2A | |
| SCHEMBL8972064 | 0.78 | PPM1B (0.37) | CHRM2CHRM4CHRM3KMT2ACYP3A4 | |
| SCHEMBL16079938 | 0.78 | CHRM2 (0.34) | CHRM2CHRM4CHRM3KMT2ACYP3A4 | |
| SCHEMBL3918398 | 0.78 | CHRM2 (0.34) | CHRM2CHRM4CHRM3KMT2ACYP3A4 | |
| SCHEMBL8969151 | 0.78 | TSHR (0.33) | TSHR | |
| SCHEMBL8970421 | 0.78 | CYP1A2 (0.36) | KMT2ACYP1A2TSHRHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-108368081-B | Andrographolide modified compound | 黑龙江珍宝岛药业股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | MEDSHINE DISCOVERY INC. (CN) | 2018-12-06 | — | — | US | disclosed |
| US-20090137822-A1 | Process for preparing 3-substituted thiophene | UBE INDUSTRIES, LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-0376294-B1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI LTD (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5370821-A | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5269965-A | Optically active compounds, liquid crystal compositions comprising said compounds and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0376294-A1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI, LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | CHRM2 4736/4885CHRM4 4780/4885CHRM3 4464/4885 |
| US-10717720-B2 | Modified compound of andrographolide | CYP11B2, CYP11B1, DUSP23 | CHRM2 3835/4885CHRM4 4525/4885CHRM3 3883/4885 |
| US-20090137822-A1 | Process for preparing 3-substituted thiophene | TMT1A, CTH, CBR1 | CHRM2 2231/4885CHRM4 1712/4885CHRM3 1714/4885 |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | CYP11B2, CYP11B1, DUSP23 | CHRM2 3835/4885CHRM4 4525/4885CHRM3 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.